{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:58:23Z","timestamp":1791665903854,"version":"4.3.4"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/3-014-01\/503-31-001"],"award-info":[{"award-number":["503\/3-014-01\/503-31-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/3-021-01\/503-31-001"],"award-info":[{"award-number":["503\/3-021-01\/503-31-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118334","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:47:57Z","timestamp":1762012077000},"page":"118334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"P2","title":["Valproic acid as a therapeutic scaffold: Advances in structural modification and drug design"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-4522","authenticated-orcid":false,"given":"Aleksandra","family":"Trocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota G.","family":"Piotrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Markowicz-Piasecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118334_bib1","first-page":"5","article-title":"The history of valproate in clinical neuroscience","volume":"37","author":"Thomas","year":"2003","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.ejmech.2025.118334_bib2","first-page":"435","article-title":"Pharmacodynamic properties of N-dipropylacetic acid","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1016\/j.ejmech.2025.118334_bib3","first-page":"577","article-title":"First clinical trials of the antiepileptic activity of N-dipropylacetic acid","volume":"122","author":"Carraz","year":"1964","journal-title":"Ann. Med. Psychol. (Paris)"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118334_bib4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJM198003203021204","article-title":"Drug therapy: valproic acid","volume":"302","author":"Kochweser","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib6","first-page":"CD003196","article-title":"Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder","author":"Cipriani","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tips.2007.02.005","article-title":"Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms","volume":"28","author":"Calabresi","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118334_bib8","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American academy of neurology, the American association of neuromuscular and electrodiagnostic medicine, and the American academy of physical medicine and rehabilitation","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action","volume":"58","author":"L\u00f6scher","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2025.118334_bib10","series-title":"Valproic Acid","author":"Rahman","year":"2025"},{"key":"10.1016\/j.ejmech.2025.118334_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","article-title":"Inhibitors of histone deacetylase as antitumor agents: a critical review","volume":"67","author":"Manal","year":"2016","journal-title":"Bioorg. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118334_bib12","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.ejmech.2025.118334_bib13","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118334_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/bdrb.20053","article-title":"Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity","volume":"74","author":"Menegola","year":"2005","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.reprotox.2011.09.007","article-title":"Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice","volume":"32","author":"Khan","year":"2011","journal-title":"Reprod. Toxicol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib18","first-page":"1","article-title":"Effects of royal jelly on genotoxicity and nephrotoxicity induced by valproic acid in albino mice","volume":"3","author":"Galaly","year":"2014","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib19","first-page":"61","article-title":"Genotoxity evaluation in female patients on valproic acid monotherapy using alkaline cell gel electrophoresis","volume":"5","author":"Denli","year":"2000","journal-title":"Eastern J. Med."},{"key":"10.1016\/j.ejmech.2025.118334_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2020.104091","article-title":"Efficacy and safety of valproic acid in dementia: a systematic review with meta-analysis","volume":"89","author":"Liu","year":"2020","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib21","first-page":"13","article-title":"Evaluation of in vitro antibacterial activity of anticonvulsant drugs","volume":"4","author":"Nathiya","year":"2015","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.ejmech.2025.118334_bib22","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fmicb.2017.01956","article-title":"pH-dependant antifungal activity of valproic acid against the human fungal pathogen Candida albicans","volume":"8","author":"Chaillot","year":"2017","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainresbull.2009.09.003","article-title":"Valproic acid as a promising agent to combat Alzheimer's disease","volume":"81","author":"Zhang","year":"2010","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib24","first-page":"262","article-title":"The use of valproic acid and multiple sclerosis, pharmacoepidemiol","volume":"24","author":"Nielsen","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2025.118334_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0014-2999(84)90243-7","article-title":"Comparative-evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy","volume":"99","author":"L\u00f6scher","year":"1984","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118334_bib26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/jps.2600821214","article-title":"Anticonvulsant and neurotoxic activities of 12 analogs of valproic acid","volume":"82","author":"Elmazar","year":"1993","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118334_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03602538109011082","article-title":"Inhibitors of cytochrome P-450s and their mechanism of action","volume":"12","author":"Testa","year":"1981","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2025.118334_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF01962708","article-title":"Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in healthy male volunteers","volume":"14","author":"D\u00fcsing","year":"1992","journal-title":"Pharm. Weekbl. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/jm00382a004","article-title":"Spiro[4.5] and spiro[4.6] carboxylic-acids \u2013 cyclic analogs of valproic acid \u2013 synthesis and anticonvulsant evaluation","volume":"28","author":"Scott","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118334_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0028-3908(85)90028-0","article-title":"Pharmacological evaluation of various metabolites and analogs of valproic acid \u2013 anticonvulsant and toxic potencies in mice","volume":"24","author":"L\u00f6scher","year":"1985","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118334_bib31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1023\/A:1015934321764","article-title":"Structure\u2013pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity","volume":"6","author":"Haj-Yehia","year":"1989","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2025.118334_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0272-0590(86)90180-6","article-title":"Pharmacological evaluation of various metabolites and analogs of valproic acid \u2013 teratogenic potencies in mice","volume":"6","author":"Nau","year":"1986","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118334_bib33","first-page":"47","article-title":"Amidic modification of valproic acid reduces skeletal teratogenicity in mice, Birth Defects Res. Part B Dev","volume":"71","author":"Okada","year":"2004","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118334_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-199120020-00003","article-title":"Clinical pharmacology of valpromide","volume":"20","author":"Bialer","year":"1991","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118334_bib35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ntt.2008.03.060","article-title":"Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity","volume":"30","author":"Gravemann","year":"2008","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.ejmech.2025.118334_bib36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0022-3565(24)36958-7","article-title":"Time course of \u03b1-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal \u03b3-aminobutyric acid levels in comparison to valproic acid","volume":"282","author":"Tang","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-1211(97)00095-8","article-title":"Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid","volume":"30","author":"Radatz","year":"1998","journal-title":"Epilepsy Res."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118334_bib38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/bdr2.1406","article-title":"Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice","volume":"111","author":"Lin","year":"2019","journal-title":"Birth Defects Res"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/epi.12480","article-title":"Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential","volume":"55","author":"Ahmad","year":"2014","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118334_bib40","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/ijms18091912","article-title":"Mitochondrial liver toxicity of valproic acid and its acid derivatives is related to inhibition of \u03b1-lipoamide dehydrogenase","volume":"18","author":"Kudin","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1528-1167.2011.03338.x","article-title":"A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage","volume":"53","author":"White","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejmech.2025.118334_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.11.005","article-title":"A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus","volume":"231","author":"Pouliot","year":"2013","journal-title":"Neuroscience"},{"issue":"16","key":"10.1016\/j.ejmech.2025.118334_bib43","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1021\/jm4007565","article-title":"Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus","volume":"56","author":"Hen","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118334_bib44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.yebeh.2015.02.040","article-title":"Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide \u2013 amide derivatives of valproic acid","volume":"46","author":"Mawasi","year":"2015","journal-title":"Epilepsy Behav."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib45","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1023\/A:1018960722284","article-title":"Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid","volume":"16","author":"Spiegelstein","year":"1999","journal-title":"Pharm. Res."},{"issue":"25","key":"10.1016\/j.ejmech.2025.118334_bib46","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1021\/jm7009233","article-title":"Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid","volume":"50","author":"Shimshoni","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118334_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1023\/A:1007577600088","article-title":"Structure\u2013activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid","volume":"17","author":"Spiegelstein","year":"2000","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1012009012850","article-title":"Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives","volume":"14","author":"Levi","year":"1997","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib49","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1023\/A:1012383125480","article-title":"Synthesis of valproic acid amides of a melatonin derivative, a piracetam and amantadine for biological tests","volume":"26","author":"Chatterjie","year":"2001","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2025.118334_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eplepsyres.2003.10.015","article-title":"Teratogenicity of valproate conjugates with anticonvulsant activity in mice","volume":"57","author":"Spiegelstein","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejmech.2025.118334_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115033","article-title":"Anti-epileptic activity, toxicity and teratogenicity in CD1 mice of a novel valproic acid arylamide derivative, N-(2-hydroxyphenyl)-2-propylpentanamide","volume":"399","author":"Crist\u00f3bal-Luna","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118334_bib52","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eplepsyres.2011.10.005","article-title":"Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue","volume":"98","author":"Shekh-Ahmad","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejmech.2025.118334_bib53","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.bmc.2004.05.003","article-title":"Characterization of the anticonvulsant profile of valpromide derivatives","volume":"12","author":"Tasso","year":"2004","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib54","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1021\/jm100170w","article-title":"Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide","volume":"53","author":"Hen","year":"2010","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/bdrb.21068","article-title":"Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice","volume":"98","author":"Onishi","year":"2013","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib56","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.yebeh.2011.08.026","article-title":"Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid","volume":"22","author":"Pessah","year":"2011","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1528-1167.2009.02241.x","article-title":"Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative","volume":"51","author":"Shimshoni","year":"2010","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118334_bib58","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/bdrb.20209","article-title":"Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice","volume":"86","author":"Okada","year":"2009","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118334_bib59","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1023\/A:1016277507865","article-title":"Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine","volume":"12","author":"Hadad","year":"1995","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118334_bib60","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1023\/A:1012143631873","article-title":"The disposition of valproyl glycinamide and valproyl glycine in rats","volume":"14","author":"Blotnik","year":"1997","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0920-1211(00)00171-6","article-title":"Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)","volume":"43","author":"Bialer","year":"2001","journal-title":"Epilepsy Res."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118334_bib62","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/(SICI)1099-081X(199710)18:7<557::AID-BDD48>3.0.CO;2-D","article-title":"Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide","volume":"18","author":"Hadad","year":"1997","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejmech.2025.118334_bib63","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jps.2600790814","article-title":"Structure\u2013pharmacokinetic relationships in a series of short fatty-acid amides that possess anticonvulsant activity","volume":"79","author":"Haj-Yehia","year":"1990","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118334_bib64","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/(SICI)1099-081X(199610)17:7<565::AID-BDD979>3.0.CO;2-I","article-title":"Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid","volume":"17","author":"Bialer","year":"1996","journal-title":"Biopharm. Drug Dispos."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib65","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/jps.2600811019","article-title":"Pharmacokinetic analysis of ester prodrugs of valproic acid","volume":"81","author":"Hadad","year":"1992","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/bdd.2510140105","article-title":"Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid","volume":"14","author":"Hadad","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejmech.2025.118334_bib67","first-page":"169","article-title":"In-vitro release and pharmacological study of synthesized valproic acid\u2013dextran conjugate","volume":"51","author":"Praveen","year":"2009","journal-title":"Acta Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118334_bib68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/tx00047a006","article-title":"Fluorinated analogs as mechanistic probes in valproic acid hepatotoxicity \u2013 hepatic microvesicular steatosis and glutathione status","volume":"8","author":"Tang","year":"1995","journal-title":"Chem. Res. Toxicol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0009-9120(01)00217-X","article-title":"CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity","volume":"34","author":"Neuman","year":"2001","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib70","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1023\/A:1016055517724","article-title":"Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropane analogues of valpromide","volume":"13","author":"Bialer","year":"1996","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0928-0987(97)00081-X","article-title":"Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats","volume":"6","author":"Blotnik","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118334_bib72","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1021\/jm0498351","article-title":"Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid: synthesis and evaluation of anticonvulsant activity of its amide derivatives","volume":"47","author":"Sobol","year":"2004","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/bdrb.20078","article-title":"Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice","volume":"77","author":"Okada","year":"2006","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib74","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.neuropharm.2006.06.006","article-title":"Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonylurea, a novel, second generation to valproic acid, antiepileptic drug","volume":"51","author":"Sobol","year":"2006","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eplepsyres.2006.08.004","article-title":"Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide","volume":"73","author":"Sobol","year":"2007","journal-title":"Epilepsy Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118334_bib76","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1016\/j.bmc.2008.03.051","article-title":"Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives","volume":"16","author":"Shimshoni","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118334_bib77","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/bdra.20490","article-title":"Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice","volume":"82","author":"Okada","year":"2008","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118334_bib78","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/jm900017f","article-title":"\u03b1-Fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid","volume":"52","author":"Pessah","year":"2009","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib79","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/j.1528-1167.2010.02684.x","article-title":"Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid","volume":"51","author":"Pessah","year":"2010","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(98)00108-9","article-title":"Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)","volume":"34","author":"Bialer","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejmech.2025.118334_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-1211(02)00106-7","article-title":"Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)","volume":"51","author":"Bialer","year":"2002","journal-title":"Epilepsy Res."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib82","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bbalip.2013.01.008","article-title":"Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder","volume":"1831","author":"Modi","year":"2013","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejmech.2025.118334_bib83","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/tx950216s","article-title":"Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect","volume":"9","author":"Bojic","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118334_bib85","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial","volume":"12","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disord."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118334_bib86","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.neuropharm.2010.03.004","article-title":"Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid","volume":"58","author":"Kaufmann","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2025.118334_bib87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.phrs.2016.11.030","article-title":"Sec-butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain","volume":"117","author":"Kaufmann","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib88","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.11.020","article-title":"Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide","volume":"54","author":"Kaufmann","year":"2008","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118334_bib89","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neuropharm.2005.06.008","article-title":"Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain","volume":"49","author":"Winkler","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2025.118334_bib90","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.bjp.0706310","article-title":"Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain","volume":"146","author":"Winkler","year":"2005","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib91","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1177\/0333102415612773","article-title":"Sec-butylpropylacetamide (SPD) has antimigraine properties","volume":"36","author":"Kaufmann","year":"2016","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118334_bib92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.118334_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.687362","article-title":"Valproic acid: a promising therapeutic agent in glioma treatment","volume":"11","author":"Han","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118334_bib94","first-page":"1167","article-title":"Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells, Leuk","volume":"30","author":"Deubzer","year":"2006","journal-title":"Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib95","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00204-012-0930-3","article-title":"Enantioselective apoptosis induction in histiocytic lymphoma cells and acute promyelocytic leukemia cells","volume":"87","author":"Ivanova","year":"2013","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib96","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1021\/tx0502241","article-title":"Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure\u2013activity relationships of 20 valproic acid derivatives","volume":"19","author":"Eikel","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118334_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2020.102940","article-title":"2-Hexyl-4-pentynoic acid, a potential therapeutic for breast carcinoma by influencing RPA2 hyperphosphorylation-mediated DNA repair","volume":"95","author":"Ding","year":"2020","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2025.118334_bib98","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.radmp.2023.10.003","article-title":"Hexyl-pentynoic acid serves as a novel radiosensitizer for breast cancer by inhibiting UCHL3-dependent Rad51 deubiquitination","volume":"4","author":"Cai","year":"2023","journal-title":"Radiat. Med. Prot."},{"issue":"22","key":"10.1016\/j.ejmech.2025.118334_bib99","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1021\/jm901181h","article-title":"Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine","volume":"52","author":"Bender","year":"2009","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/1535-7163.MCT-12-0654","article-title":"Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts","volume":"12","author":"Pratt","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118334_bib101","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1007\/s00044-016-1635-6","article-title":"Design and synthesis of taxane derivatives of valproic acid as potent and selective cytotoxic agents","volume":"25","author":"Malipeddi","year":"2016","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118334_bib102","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/14756366.2016.1210138","article-title":"N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells","volume":"31","author":"Prestegui-Martel","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"70","key":"10.1016\/j.ejmech.2025.118334_bib103","doi-asserted-by":"crossref","first-page":"33368","DOI":"10.18632\/oncotarget.26077","article-title":"N-(2\u2032-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells","volume":"9","author":"de Oca","year":"2018","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.ejmech.2025.118334_bib104","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.3390\/ijms21165873","article-title":"N-(2\u2032-Hydroxyphenyl)-2-propylpentanamide (HO-AAVPA) inhibits HDAC1 and increases the translocation of HMGB1 levels in human cervical cancer cells","volume":"21","author":"Sixto-L\u00f3pez","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118334_bib105","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.3390\/molecules28176282","article-title":"Hepatotoxic evaluation of N-(2-hydroxyphenyl)-2-propylpentanamide: a novel derivative of valproic acid for the treatment of cancer","volume":"28","author":"Basurto","year":"2023","journal-title":"Molecules"},{"issue":"20","key":"10.1016\/j.ejmech.2025.118334_bib106","doi-asserted-by":"crossref","first-page":"12391","DOI":"10.1039\/C7RA00048K","article-title":"Novel valproic aminophenol amides with enhanced glial cell viability effect","volume":"7","author":"Alpuche-Garc\u00eda","year":"2017","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib107","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bcp.2014.01.023","article-title":"A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo","volume":"88","author":"Tarasenko","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118334_bib108","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10637-017-0448-x","article-title":"Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft","volume":"35","author":"Tarasenko","year":"2017","journal-title":"Invest. New Drugs"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118334_bib109","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/ph14121244","article-title":"Valproic acid prodrug affects selective markers, augments doxorubicin anticancer activity and attenuates its toxicity in a murine model of aggressive breast cancer","volume":"14","author":"Tarasenko","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118334_bib110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.semcancer.2007.04.001","article-title":"Dietary histone deacetylase inhibitors: from cells to mice to man","volume":"17","author":"Dashwood","year":"2007","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118334_bib111","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bmcl.2008.02.007","article-title":"New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity","volume":"18","author":"Perrino","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6A","key":"10.1016\/j.ejmech.2025.118334_bib112","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1582-4934.2008.00271.x","article-title":"New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma","volume":"12","author":"Wedel","year":"2008","journal-title":"J. Cell Mol. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib113","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1002\/jcp.24039","article-title":"Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity","volume":"227","author":"Tesei","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2025.118334_bib114","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07426.x","article-title":"Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells","volume":"144","author":"Bouzar","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.ejmech.2025.118334_bib115","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1016\/j.bmcl.2014.09.046","article-title":"From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3\u2032-C-methyladenosine","volume":"24","author":"Petrellia","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118334_bib116","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3892\/ijo.2015.2924","article-title":"Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells","volume":"46","author":"Yamanegi","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2025.118334_bib117","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s12094-016-1494-0","article-title":"Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1\u03b1\/VEGF signals","volume":"18","author":"Zhao","year":"2016","journal-title":"Clin. Transl. Oncol."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118334_bib118","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.6b01039","article-title":"Antiangiogenic effect of (\u00b1)-haloperidol metabolite II valproate ester [(\u00b1)-MRJF22] in human microvascular retinal endothelial cells","volume":"59","author":"Olivieri","year":"2016","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118334_bib119","doi-asserted-by":"crossref","first-page":"13622","DOI":"10.1021\/acs.jmedchem.1c00995","article-title":"Haloperidol metabolite II valproate ester (S)-(-)-MRJF22: preliminary studies as a potential multifunctional agent against uveal melanoma","volume":"64","author":"Barbaraci","year":"2021","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118334_bib120","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.3390\/molecules28093936","article-title":"Synthesis and antitumor evaluation of biotin\u2013SN38\u2013valproic acid conjugates","volume":"28","author":"Dai","year":"2023","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118334_bib121","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp200597r","article-title":"Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy","volume":"9","author":"Yang","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118334_bib122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jinorgbio.2013.09.003","article-title":"Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells","volume":"129","author":"Alessio","year":"2013","journal-title":"J. Inorg. Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib123","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bcp.2015.04.003","article-title":"New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells","volume":"95","author":"Novohradsky","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118334_bib124","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jinorgbio.2014.07.004","article-title":"Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands","volume":"140","author":"Novohradsky","year":"2014","journal-title":"J. Inorg. Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118334_bib125","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1039\/C5SC04205D","article-title":"Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action","volume":"7","author":"Raveendran","year":"2016","journal-title":"Chem. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118334_bib126","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1039\/C9QI01453E","article-title":"A class of Pt(IV) triple-prodrugs targeting nucleic acids, thymidylate synthases and histone deacetylases","volume":"7","author":"Ding","year":"2020","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.ejmech.2025.118334_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111508","article-title":"A valproic acid-modified platinum diimine complex as potential photosensitizer for photodynamic therapy","volume":"222","author":"Liu","year":"2021","journal-title":"J. Inorg. Biochem."},{"issue":"32","key":"10.1016\/j.ejmech.2025.118334_bib128","doi-asserted-by":"crossref","first-page":"11180","DOI":"10.1039\/D1DT01421H","article-title":"ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug","volume":"50","author":"Li","year":"2021","journal-title":"Dalton Trans"},{"issue":"32","key":"10.1016\/j.ejmech.2025.118334_bib129","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1039\/D3DT01876H","article-title":"Platinum(IV) combo prodrugs containing cyclohexane-1R,2R-diamine, valproic acid, and perillic acid as a multiaction chemotherapeutic platform for colon cancer","volume":"52","author":"Gabano","year":"2023","journal-title":"Dalton Trans"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118334_bib130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfi184","article-title":"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats","volume":"86","author":"Tong","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2025.118334_bib131","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118334_bib132","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/mp2001878","article-title":"Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery","volume":"8","author":"Peura","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118334_bib133","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.1015","article-title":"Prediction of acute hepatotoxicity with human pluripotent stem cell-derived hepatic organoids","volume":"4","author":"Kim","year":"2024","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.ejmech.2025.118334_bib134","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/mutage\/geab023","article-title":"Organoids for toxicology and genetic toxicology: applications with drugs and prospects for environmental carcinogenesis","volume":"37","author":"Garcia","year":"2022","journal-title":"Mutagenesis"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:57:24Z","timestamp":1780909044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":132,"alternative-id":["S0223523425010992"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118334","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid as a therapeutic scaffold: Advances in structural modification and drug design","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118334"}}